| Literature DB >> 34365850 |
Matthew Flowers1, Albert Leung1,2, Dawn M Schiehser1,3, Valerie Metzger-Smith1, Lisa Delano-Wood1,3, Scott Sorg1,3, Alphonsa Kunnel1, Angeline Wong1, Michael Vaninetti1,2, Shahrokh Golshan1, Roland Lee4.
Abstract
Emerging evidence suggests mild traumatic brain injury related headache (MTBI-HA) is a form of neuropathic pain state. Previous supraspinal mechanistic studies indicate patients with MTBI-HA demonstrate a dissociative state with diminished levels of supraspinal prefrontal pain modulatory functions and enhanced supraspinal sensory response to pain in comparison to healthy controls. However, the relationship between supraspinal pain modulatory functional deficit and severity of MTBI-HA is largely unknown. Understanding this relationship may provide enhanced levels of insight about MTBI-HA and facilitate the development of treatments. This study assessed pain related supraspinal resting states among MTBI-HA patients with various headache intensity phenotypes with comparisons to controls via functional magnetic resonance imaging (fMRI). Resting state fMRI data was analyzed with self-organizing-group-independent-component-analysis in three MTBI-HA intensity groups (mild, moderate, and severe) and one control group (n = 16 per group) within a pre-defined supraspinal pain network based on prior studies. In the mild-headache group, significant increases in supraspinal function were observed in the right premotor cortex (T = 3.53, p < 0.001) and the left premotor cortex (T = 3.99, p < 0.0001) when compared to the control group. In the moderate-headache group, a significant (T = -3.05, p < 0.01) decrease in resting state activity was observed in the left superior parietal cortex when compared to the mild-headache group. In the severe-headache group, significant decreases in resting state supraspinal activities in the right insula (T = -3.46, p < 0.001), right premotor cortex (T = -3.30, p < 0.01), left premotor cortex (T = -3.84, p < 0.001), and left parietal cortex (T = -3.94, p < 0.0001), and an increase in activity in the right secondary somatosensory cortex (T = 4.05, p < 0.0001) were observed when compared to the moderate-headache group. The results of the study suggest that the increase in MTBI-HA severity may be associated with an imbalance in the supraspinal pain network with decline in supraspinal pain modulatory function and enhancement of sensory/pain decoding.Entities:
Keywords: MTBI; chronic post-traumatic headache; functional magnetic resonance imaging; pain modulation; resting state functional activity; traumatic brain injury
Mesh:
Year: 2021 PMID: 34365850 PMCID: PMC8358489 DOI: 10.1177/17448069211037881
Source DB: PubMed Journal: Mol Pain ISSN: 1744-8069 Impact factor: 3.395
Figure 1.Imaging data acquisition, processing and analysis flow chart. ACPC: Anterior Commissure-Posterior Commissure; fMRI: functional magnetic resonance imaging; GLM: general linear model; VOI: volume of interest; ANOVA: analysis of variance.
Group demographics.
Severity of MTBI-HA | ||||
|---|---|---|---|---|
| Controls(n = 16) | Mild(n = 16) | Moderate(n = 16) | Severe(n = 16) | |
| Demographic characteristics | ||||
| Age (years) | 32.06 (5.86) | 32.75 (5.56) | 33.06 (6.10) | 32.63 (5.74) |
| Sex (N male) | 16 | 16 | 16 | 16 |
| Education (years) | 14.81 (1.60) | 14.19 (2.17) | 13.16 (0.93) | 14.06 (1.65) |
| Ethnicity | ||||
| % Hispanic/Latino | 19% | 25% | 25% | 44% |
| % Not Hispanic/Latino | 81% | 75% | 75% | 56% |
| MTBI characteristics | ||||
| Headache duration since most significant MTBI (months) | N/A | 81.25 (53.57) | 103.06 (59.71) | 90.63 (53.80) |
| MTBI mechanism | ||||
| % non-blast | N/A | 44% | 50% | 13% |
| % blast | N/A | 31% | 50% | 31% |
| % both | N/A | 25% | 0% | 56% |
| Mood | ||||
| Depression | ||||
| % minimal | 56% | 50% | 13% | 13% |
| % mild | 19% | 13% | 19% | 19% |
| % moderate | 13% | 31% | 38% | 19% |
| % severe | 13% | 6% | 31% | 50% |
| % clinical PTSD diagnosis | 25% | 31% | 69% | 88% |
All variables reported means and standard deviations unless otherwise indicated; N = number.
Group demographic comparison P-values (all pair-wise comparisons were corrected).
| Overall | Control vs mild | Control vs moderate | Control vs severe | Mild vs moderate | Mild vs severe | Moderate vs severe | |
|---|---|---|---|---|---|---|---|
| Demographic characteristics | |||||||
| Age | 0.969 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Education | 0.050 | 1.000 |
| 1.000 | 0.489 | 1.000 | 0.749 |
| Ethnicity | 0.426 | 1.000 | 1.000 | 0.763 | 1.000 | 1.000 | 1.000 |
| MTBI characteristics | |||||||
| MTBI headache Duration | 0.545 | N/A | N/A | N/A | 0.823 | 1.000 | 1.000 |
| MTBI type |
| N/A | N/A | N/A | 0.278 | 0.286 |
|
| Mood | |||||||
| Depression |
| 1.000 | 0.310 | 0.246 | 0.525 | 0.125 | 1.000 |
| Clinical PTSD diagnosis |
| 1.000 | 0.079 |
| 0.203 |
| 1.000 |
* indicates the bold typed P value is less than 0.05.N/A - Control subjects did not have TBI therefore statistical analysis was not conducted.
Pairwise group medication comparison (P-values) between various MTBI-HA intensity groups.
| Medication | All MTBI-HA | Mild vs moderate | Mild vs severe | Moderate vs severe |
|---|---|---|---|---|
| GABA | 0.344 | 1.000 | 1.000 | 1.000 |
| SSRI | 0.102 | 0.304 | 1.000 | 1.000 |
| TCA | 0.102 | 1.000 | 1.000 | 0.304 |
| ACET | 0.344 | 1.000 | 1.000 | 1.000 |
| NSAIDS | 0.438 | 1.000 | 1.000 | 1.000 |
| TeCA | 0.148 | 1.000 | 1.000 | 0.677 |
| TRIPTAN | 0.106 | 0.998 | 0.249 | 1.000 |
| TOP | 0.360 | ‡ | 1.000 | 1.000 |
| AED | 0.210 | 0.677 | 1.000 | 1.000 |
| Benzo | 0.344 | 1.000 | 1.000 | 1.000 |
| OPIOID | 0.593 | 1.000 | 1.000 | 1.000 |
| NERI | 0.124 | ‡ | 1.000 | 1.000 |
| AP | 0.593 | 1.000 | 1.000 | 1.000 |
| AMP | 0.360 | 1.000 | ‡ | 1.000 |
Values based on number of medications taken.
‡No statistics computed because medication is a constant.
All medication measures were non-significant with p > 0.05.
p-values calculated with chi-square tests or Fisher’s exact test where appropriate.
GABA, gamma-Aminobutyric acid; SSRI, Selective serotonin reuptake inhibitors; TCA, Tricyclic antidepressants; ACET, Acetaminophen; NSAIDS, Nonsteroidal anti-inflammatory drugs, TeCA, Tetracyclic antidepressants; TRIPTAN, Triptans; TOP, Topical Lidocaine: AED, Anti-epileptic drugs; Benzo, Benzodiazepines; OPIOID, Opioids; NERI, norepinephrine reuptake inhibitor; AP, Antipsychotic; AMP, Amphetamine.
Figure 2.Differences in cortical activity between headache severity groups. Glass brains illustrate areas of more activation in orange and areas of less activation in blue. (a) The areas of activation in the mild vs. control headache severity with the control group as baseline for comparison. (b) The areas of activation in the moderate vs. mild headache severity with the mild group as baseline for comparison. (c) The areas of activation in the severe vs. moderate headache severity with the moderate group as baseline for comparison.